Literature DB >> 26136458

Cardiomyocyte A Disintegrin And Metalloproteinase 17 (ADAM17) Is Essential in Post-Myocardial Infarction Repair by Regulating Angiogenesis.

Dong Fan1, Abhijit Takawale1, Mengcheng Shen1, Wang Wang1, Xiuhua Wang1, Ratnadeep Basu1, Gavin Y Oudit1, Zamaneh Kassiri2.   

Abstract

BACKGROUND: A disintegrin and metalloproteinase 17 (ADAM17) is a membrane-bound enzyme that mediates shedding of many membrane-bound molecules, thereby regulating multiple cellular responses. We investigated the role of cardiomyocyte ADAM17 in myocardial infarction (MI). METHODS AND
RESULTS: Cardiomyocyte-specific ADAM17 knockdown mice (ADAM17(flox/flox)/α-MHC-Cre; f/f/Cre) and parallel controls (ADAM17(flox/flox); f/f) were subjected to MI by ligation of the left anterior descending artery. Post MI, f/f/Cre mice showed compromised survival, higher rates of cardiac rupture, more severe left ventricular dilation, and suppressed ejection fraction compared with parallel f/f-MI mice. Ex vivo ischemic injury (isolated hearts) resulted in comparable recovery in both genotypes. Myocardial vascular density (fluorescent-labeled lectin perfusion and CD31 immunofluorescence staining) was significantly lower in the infarct areas of f/f/Cre-MI compared with f/f-MI mice. Activation of vascular endothelial growth factor receptor 2 (VEGFR2), its mRNA, and total protein levels were reduced in infarcted myocardium in ADAM17 knockdown mice. Transcriptional regulation of VEGFR2 by ADAM17 was confirmed in cocultured cardiomyocyte-fibroblast as ischemia-induced VEGFR2 expression was blocked by ADAM17-siRNA. Meanwhile, ADAM17-siRNA did not alter VEGFA bioavailability in the conditioned media. ADAM17 knockdown mice (f/f/Cre-MI) exhibited reduced nuclear factor-κB activation (DNA binding) in the infarcted myocardium, which could underlie the suppressed VEGFR2 expression in these hearts. Post MI, inflammatory response was not altered by ADAM17 downregulation.
CONCLUSIONS: This study highlights the key role of cardiomyocyte ADAM17 in post-MI recovery by regulating VEGFR2 transcription and angiogenesis, thereby limiting left ventricular dilation and dysfunction. Therefore, ADAM17 upregulation, within the physiological range, could provide protective effects in ischemic cardiomyopathy.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  cardiac remodeling; inflammation; myocardial infarction; tumor necrosis factor-alpha convertase; vascular endothelial growth factor receptor-2

Mesh:

Substances:

Year:  2015        PMID: 26136458     DOI: 10.1161/CIRCHEARTFAILURE.114.002029

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  17 in total

1.  Degradome of soluble ADAM10 and ADAM17 metalloproteases.

Authors:  Franka Scharfenberg; Andreas Helbig; Martin Sammel; Julia Benzel; Uwe Schlomann; Florian Peters; Rielana Wichert; Maximilian Bettendorff; Dirk Schmidt-Arras; Stefan Rose-John; Catherine Moali; Stefan F Lichtenthaler; Claus U Pietrzik; Jörg W Bartsch; Andreas Tholey; Christoph Becker-Pauly
Journal:  Cell Mol Life Sci       Date:  2019-06-17       Impact factor: 9.261

2.  Cardiomyocyte-specific deficiency of HSPB1 worsens cardiac dysfunction by activating NFκB-mediated leucocyte recruitment after myocardial infarction.

Authors:  Yana Wang; Jiali Liu; Qiuyue Kong; Hao Cheng; Fei Tu; Peng Yu; Ying Liu; Xiaojin Zhang; Chuanfu Li; Yuehua Li; Xinxu Min; Shuya Du; Zhengnian Ding; Li Liu
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

Review 3.  A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease.

Authors:  Sheng Zhong; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2019-03-21       Impact factor: 5.858

Review 4.  The Role of ADAM17 in Inflammation-Related Atherosclerosis.

Authors:  Bai-Yi Tang; Jin Ge; Yang Wu; Juan Wen; Xiao-Hong Tang
Journal:  J Cardiovasc Transl Res       Date:  2022-06-01       Impact factor: 4.132

5.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

6.  The allosteric glycogen synthase kinase-3 inhibitor NP12 limits myocardial remodeling and promotes angiogenesis in an acute myocardial infarction model.

Authors:  Jugajyoti Baruah; Ryan Hitzman; Jane Zhang; Suhnrita Chaudhuri; Victoria Mastej; Kishore K Wary
Journal:  J Biol Chem       Date:  2017-10-25       Impact factor: 5.157

7.  ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.

Authors:  Roopali Roy; Adelle Dagher; Catherine Butterfield; Marsha A Moses
Journal:  Mol Cancer Res       Date:  2017-08-01       Impact factor: 5.852

8.  β1-adrenergic receptor N-terminal cleavage by ADAM17; the mechanism for redox-dependent downregulation of cardiomyocyte β1-adrenergic receptors.

Authors:  Jing Zhu; Susan F Steinberg
Journal:  J Mol Cell Cardiol       Date:  2021-02-06       Impact factor: 5.000

Review 9.  Reversion inducing cysteine rich protein with Kazal motifs and cardiovascular diseases: The RECKlessness of adverse remodeling.

Authors:  Jacob J Russell; Laurel A Grisanti; Scott M Brown; Chastidy A Bailey; Shawn B Bender; B Chandrasekar
Journal:  Cell Signal       Date:  2021-03-27       Impact factor: 4.850

Review 10.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.